Bain Capital Life Sciences

BitradeX is a digital asset trading platform powered by AI technology, dedicated to redefining digital asset trading through innovative AI algorithms and blockchain technology.

Sizzling Platter, LLC is a food and beverage company that owns and manages a diverse range of fast casual restaurants in the United States and internationally. Founded in 1963 and headquartered in Murray, Utah, the company offers a variety of menu items, including pizzas, donuts, coffee, burgers, steak, seafood, and salads. Sizzling Platter focuses on acquiring and supporting various restaurant brands, providing them with the resources needed for growth and enhanced return on capital. The company is committed to delivering a quick service and casual dining experience at affordable prices, while also engaging in community initiatives such as donating food to those in need.

Merida Biosciences is a new biotech company focused on developing precision treatments, particularly for autoimmune diseases. The company utilize a protein engineering platform to create unique Fc therapeutics, aiming to selectively bind to specific antibodies.

HealthEdge provides modern, disruptive technology that delivers for the first time, a suite of products that enables healthcare payors to leverage new business models, improve outcomes, drastically reduce administrative costs, and connect everyone in the healthcare delivery cycle. Their next-generation enterprise product suite, HealthRules, is built on modern, patented technology and is delivered to customers via the HealthEdge Cloud or on-site deployment. They enable their customers to radically innovate, drastically reduce costs, and efficiently address the business imperatives of the evolving healthcare economy. HealthEdge was founded by Albert Waxman of Psilos Group and Rob Gillette in December 2004. In January 2005, the company acquired over $125 million in intellectual property and other assets. This technology served as the foundation for the patented, award-winning HealthRules product suite. In December 2012, HealthEdge acquired Click4Care, a care management, and utilization management software company, adding next-generation clinical capabilities to the award-winning HealthRules product suite. HealthEdge is headquartered in Burlington, Massachusetts, and maintains an R&D center in Powell, Ohio.

Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases that can lead to blindness. Their clinical pipeline includes therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Atsena employs an adeno-associated virus (AAV) technology platform, including a novel spreading capsid, to specifically target these retinal disorders. The company aims to prevent vision loss caused by genetic mutations through innovative ocular gene therapy solutions. With a commitment to advancing treatments for some of the most challenging forms of inherited retinal disease, Atsena Therapeutics seeks to improve the lives of patients affected by these conditions.

Namirial specializes in digital transaction management software aimed at facilitating the digital transformation of business processes for both private sector companies and public administration organizations. The company's platform offers a range of services, including identity management, electronic signatures, certified communication, document management, electronic invoicing, and cybersecurity. By providing these tools, Namirial enables organizations to manage and execute document-centric transactions and business processes entirely in a digital format, enhancing efficiency and security in their operations.

HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.

Norm AI offers an AI-driven regulatory compliance platform tailored for the legal and compliance sectors. The platform addresses the regulatory sludge problem by transforming complex regulations into AI agents capable of making autonomous compliance decisions. This allows compliance teams to assign tasks to the regulatory AI using high-level instructions, while ensuring the quality of the output through validation at various levels of detail. Norm AI’s innovative solutions streamline compliance processes, improving efficiency and accuracy for organizations navigating intricate regulatory landscapes.

Surf Internet offers fiber and fixed wireless broadband services to residential and business customers in Indiana, Illinois, and Michigan. The company provides a variety of internet plans tailored to different usage needs, ensuring reliable connectivity for activities such as streaming, gaming, and remote work. In addition to broadband internet, Surf Internet also offers digital phone services. The company is committed to expanding its network infrastructure to improve service availability and performance while prioritizing customer support for installation and technical issues. Through its efforts, Surf Internet aims to enhance the quality of life in the Great Lakes region by delivering high-speed internet solutions to communities.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients’ muscles. DMD is a progressive and ultimately fatal condition, with an estimated prevalence of 10,000 to 15,000 cases in the United States. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which targets the LTBP4 protein to reduce fibrosis and inflammation. The company also develops biomarkers, sensors, and the Solid Suit program, which includes wearable assistive devices designed to provide functional and therapeutic benefits. Established in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences collaborates with Ultragenyx to enhance its gene therapy initiatives for DMD.

Apleona is an integrated real estate service provider operating primarily in the DACH region, offering a comprehensive range of services to banks, investment funds, industrial firms, and insurance companies. Established in 2016 and headquartered in Neu Isenburg, Hessen, the company specializes in technical facility services, including facility management, building technology, and interior fittings. Apleona's offerings extend to real estate management, encompassing commercial services such as letting, leasing, and marketing of properties. With a focus on enhancing performance across national borders, Apleona aims to meet the diverse needs of its clients in the real estate sector.

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

SelectQuote Insurance Services, Inc. is a San Francisco-based company that specializes in marketing term life insurance products and a range of other insurance services, including auto, home, and Medicare insurance. Founded in 1985, the company operates as a subsidiary of SelectQuote, Inc. SelectQuote aims to assist families in finding the best insurance rates by comparing options from a wide array of highly rated insurance providers. This direct-to-consumer platform allows clients to shop for various insurance policies online, ensuring tailored solutions that meet individual needs and budget constraints. The company generates revenue by earning commissions from insurance carriers for the products it sells. Its operations are organized into four segments: Senior, Healthcare Services, Life, and Auto & Home.

Frontline Road Safety provides pavement marking services to a variety of end markets and customers. It's companies provide a range of services, including seal coating, pressure washing, and parking lot striping. The company was formed in 2020 by the private equity firm Sterling Group.

Jamco is a Japan-based manufacturer specializing in components for the aviation industry. The company operates through several business divisions, including Aircraft Interiors, Aircraft Seats, Aircraft Components, and Aircraft Maintenance. Its Aircraft Interiors division produces items such as galleys and lavatories for passenger aircraft, while the Aircraft Seat division focuses on the manufacturing and sales of passenger seats. The Aircraft Components division is involved in the production of critical engine components, including heat exchangers and various aircraft equipment. Additionally, the Aircraft Maintenance division provides maintenance and alteration services to ensure the safety and efficiency of aircraft operations. Jamco is committed to enhancing air travel comfort and safety through its innovative technologies and high-quality products.

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company that develops and commercializes revolutionary medicines for autoimmune illnesses. The company utilizes its team's experience in drug development to secure top-tier assets focused on promising targets, and implementing them in disease areas with considerable unmet needs.

Mayapada Hospital offers health and hospital management services. They provide a range of services ranging from diagnosis, therapy, surgery, and rehabilitation to comprehensive care and control of neurological disorders. They offer clinical services and medical consultations for digestive tract problems. Their paediatric centre also provides physical check-ups, vaccinations, and treatment for specific paediatric symptoms, heart failure, and orthopaedic disorders.

Angitia Biopharmaceuticals is a global biotechnology company dedicated to discovering and developing innovative therapeutics for serious musculoskeletal diseases. The company focuses on researching and creating breakthrough therapies aimed at treating conditions affecting bones, muscles, and joints. By prioritizing the development of novel drugs, Angitia Biopharmaceuticals aims to improve patient outcomes and facilitate recovery from severe musculoskeletal ailments.

Pollo Tropical has been committed to providing fresh, great-tasting dishes in its kitchens every day. Authentic preparation, fresh ingredients, and a creative touch on traditional flavors are the perfect mix for delicious, craveable food.

Wrightwell operates as a services platform that offers customizable, institutional access to a multi-trillion-dollar asset class to investors of all types and sizes. The company's services are primarily focused on asset management, construction, financial services, and real estate. Vantage's Single Family Rental (SFR) Services, backed by proprietary technology, empower investors to make SFR a significant part of their portfolio. The company also assists clients in determining leasing criteria and guidelines, such as background checks, employment documentation, and credit score minimums.

Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.

OAK Re is an international provider of reinsurance.

AQ Compute provides green and customized compute capacities powered by clean energy. The company was founded in 2020 and is based in Hamburg, Germany.

The Openwork Partnership is a provider of financial advice services.

Kailera Therapeutics is a clinical-stage biotechnology company that provides revolutionary therapies for treating obesity and related diseases. Kailera Therapeutics is advancing a range of injectable and oral GLP-1 (Glucagon-like peptide-1) therapies for obesity and related diseases.

Serán Bioscience is a contract development and manufacturing organization that specializes in providing a wide range of services to pharmaceutical and biotechnology companies. The company offers a comprehensive suite of development, analytical, and clinical manufacturing services, aimed at optimizing drug development and production processes. By catering to various aspects of pharmaceutical development, Serán Bioscience supports its clients in efficiently bringing their products to market.

Mintlify is a company that offers an AI-powered platform designed to assist developers in creating engaging and well-structured documentation for their products. By leveraging artificial intelligence, Mintlify automates the generation of documentation directly from code, allowing developers to focus on their core tasks without the burden of manual documentation. The platform is designed to be user-friendly and developer-centric, facilitating the creation of attractive public-facing documentation that enhances user experience and helps customers better understand the products. With over 7,000 companies, including notable names like Anthropic and Zapier, relying on its services, Mintlify aims to streamline the documentation process, ultimately saving time and improving the overall quality of documentation.

Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery.

Kestra Medical Technologies, Inc. specializes in the development and manufacturing of wearable medical devices designed for monitoring and managing acute medical conditions. Founded in 2014 and based in Kirkland, Washington, the company offers solutions that collect, communicate, and store patient performance data, enabling both real-time and retrospective analysis. Among its products are wearable cardioverter defibrillators, which aim to prevent sudden cardiac death and facilitate cardiac recovery in at-risk patients. Kestra Medical Technologies focuses on creating intuitive and mobile diagnostic and therapeutic technologies that support healthcare providers and enhance patient care.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Pomerium is a developer of identity-aware proxy software that enables secure access to internal applications without the need for a virtual private network (VPN). The company's software offers a standardized interface for authenticating, authorizing, and monitoring user access to any application, regardless of whether the application has built-in access control features. This allows enterprises to streamline security processes and focus on application development without the complexities of reinventing access control mechanisms. Pomerium's solutions enhance security while facilitating the use of both internal and external applications efficiently.

CereVasc, Inc. is a medical device company dedicated to developing innovative, minimally invasive treatments for neurological diseases. Founded in 2014 and based in Auburndale, Massachusetts, the company focuses on its flagship product, the eShunt System. This system provides an endovascularly deliverable cerebrospinal fluid shunt along with necessary delivery components, designed to eliminate the need for invasive surgical procedures, general anesthesia, and prolonged hospitalization associated with traditional treatments for communicating hydrocephalus. By offering a less invasive option, the eShunt System aims to enhance patient outcomes and reduce the overall costs of surgical interventions for this serious condition.

Century Therapeutics is a biotechnology company focused on developing advanced cell therapies using induced pluripotent stem cells (iPSCs) to treat various cancers, including hematologic and solid tumors. Founded in 2018 and based in Philadelphia, Pennsylvania, the company utilizes a unique allogeneic iPSC-derived cell therapy platform that integrates gene editing, protein engineering, and robust manufacturing capabilities. This innovative approach allows for the generation of modified immune effector cells, such as natural killer (NK) and T cells, designed to meet significant unmet medical needs. By employing techniques like CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to enhance cell product performance and minimize rejection by the host immune system, thereby improving the efficacy of cancer treatments.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication of improving lung function and is found in several asthma-related treatments.

Branching Minds solves a large and growing problem for teachers, principals and superintendents: educators have no clear way of figuring out why students are struggling to learn, or what teachers should do to help them get back on track. Our platform helps teachers to identify students’ cognitive learning strengths and challenges, algorithmically matches them with research-backed learning supports, and then tracks and reports data on student progress.

Accolade Wines is a global wine business headquartered in South Australia. It is recognized as the leading wine company in both Australia and the UK by volume, and ranks fifth among wine companies worldwide. Established with one of the first wineries in Australia, Accolade Wines has a rich history dating back to 1853. The company specializes in the production and distribution of a diverse range of well-known wine brands, reflecting its commitment to quality and innovation in the wine industry.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients’ muscles. DMD is a progressive and ultimately fatal condition, with an estimated prevalence of 10,000 to 15,000 cases in the United States. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which targets the LTBP4 protein to reduce fibrosis and inflammation. The company also develops biomarkers, sensors, and the Solid Suit program, which includes wearable assistive devices designed to provide functional and therapeutic benefits. Established in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences collaborates with Ultragenyx to enhance its gene therapy initiatives for DMD.

Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Eleda Group offers installation and contract services in infrastructure via companies that are local leaders. The Group’s offering is both broad and specialized, ranging from complete contracts and projects to leasing machinery, with a focus on three service areas: Civil Engineering, Transmission Infrastructure and Machinery and Transportation.

Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Gynesonics, Inc. is a medical device company that focuses on designing and developing minimally invasive solutions for symptomatic uterine fibroids in women. Established in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, the company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation for the treatment of fibroids under intrauterine sonography guidance. Gynesonics aims to provide a safe and effective incisionless alternative to traditional surgical techniques such as hysterectomy and myomectomy, thereby enabling women to receive painless treatments for severe menstrual symptoms associated with fibroids.

Long Description: Aiolos Bio is a biotech company focused on developing therapies for respiratory diseases like asthma as well as other immune conditions. The company is initially focused on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma that only requires dosing every 6 months. Aiolos Bio was founded by an accomplished team with decades of drug development experience and leadership in the biotech industry.

They are one of Vietnam’s largest private sector companies with a focus on the consumption and resources sectors. They have a track record of actively building, acquiring and managing large-scale operating platforms that capitalize on Vietnam’s structural consumption and resources stories. They believe that substantial value can be created for their shareholders through professional management, global partners and a commitment to serving Vietnam’s emerging middle class. Their vision is to become Vietnam’s local private sector champion in terms of scale, profitability, and shareholder return and to become the country’s growth partner and employer of choice. In order to achieve this vision, they operate in sectors where a local private sector company can be a market leader and can develop scale through focus and consolidation. Their management team comprises professionals with global risk management and capital allocation expertise, Vietnamese managers with local execution experience and, at their operating businesses, senior industry executives with a track record at multinational corporations.

Virgin Voyages is a lifestyle travel brand that specializes in providing luxury cruise vacations to high-end customers. The company operates a fleet of cruise ships, offering premium accommodations and a variety of entertainment options. Virgin Voyages aims to create unique and adventurous travel experiences across diverse destinations, catering to those seeking a more upscale and engaging cruise experience.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Chindata Group is a carrier-neutral hyperscale data center solution provider operating in the Asia-Pacific emerging markets, particularly in China, India, and Southeast Asia. The company specializes in delivering centralized, standardized, and modular data center solutions to prominent technology firms. Chindata Group offers a comprehensive range of services, including colocation and managed services, energy procurement, infrastructure services, and IT and network services. By establishing a full-stack and whole life-cycle partnership with its clients, the company supports them through all phases of data center development, from planning and design to construction, operation, and maintenance. This focus on meeting the evolving needs of ambitious enterprises positions Chindata Group as a key player in the data center industry.

Two Auspicious Coffee specializes on authentic Italian coffee, and their products employ Italian coffee brand KIMBO coffee beans.

Adani Housing Finance offers customized financing solutions to customers in the affordable housing segment.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

Porus Laboratories is a pharmaceutical company that specializes in the production of intermediate and active pharmaceutical ingredients for the drug industry. It manufactures a range of products, including polymers, heterogeneous and organometallic complexes, fertilizers, crop treatments, and pesticides. The company aims to meet the diverse needs of both domestic and multinational clients, serving the pharmaceutical and agriculture sectors with its specialty chemicals and intermediates.

Alkeus Pharmaceuticals is a Boston-based clinical-stage biopharmaceutical company dedicated to developing treatments for serious and untreatable ophthalmic conditions. The company's primary focus is on its lead drug candidate, an orally delivered compound aimed at addressing Stargardt disease and age-related macular degeneration. This innovative treatment has the potential to help medical professionals manage symptoms of irreversible vision loss early in life, offering hope to patients affected by these debilitating eye diseases.

IDAJ distributes and provides technical support for CAE products. IDAJ supports engineering process reform by utilizing cutting-edge MBD and CAE technologies as well as integrated solutions. IDAJ provides solutions from two technological perspectives. The first is digital engineering technologies, which fully utilize computer-based 3D design (CAD), engineering simulation (CAE), and computer-aided manufacturing (CAM). The second solution is a model-based development (MBD) process methodology, in which models (system models and CAE models) that were previously used as a substitute for prototypes or evaluations are now applied to the entire engineering process, from concept design to manufacture and service, thanks to the evolving digital environment.

CI U.S. wealth management provides financial services.

HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.

MeTEOR Education LLC, founded in 1967 and based in Gainesville, Florida, specializes in creating effective learning environments for educational institutions across the United States. The company offers a range of services that include the design, supply, and outfitting of K-12 learning spaces, such as classrooms, media centers, and STEM labs. Additionally, MeTEOR Education provides interior design services and training for educators, aimed at enhancing the educational experience and fostering meaningful interactions among students and teachers. By focusing on the development of high-impact learning experiences, MeTEOR Education supports professionals in their efforts to improve educational outcomes within their communities.

Surf Internet offers fiber and fixed wireless broadband services to residential and business customers in Indiana, Illinois, and Michigan. The company provides a variety of internet plans tailored to different usage needs, ensuring reliable connectivity for activities such as streaming, gaming, and remote work. In addition to broadband internet, Surf Internet also offers digital phone services. The company is committed to expanding its network infrastructure to improve service availability and performance while prioritizing customer support for installation and technical issues. Through its efforts, Surf Internet aims to enhance the quality of life in the Great Lakes region by delivering high-speed internet solutions to communities.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2017. The company focuses on developing human genetics-based therapeutics aimed at addressing ineffective red blood cell production in hematologic diseases. Its innovative pipeline includes therapies such as bitopertin for treating erythropoietic porphyrias and Diamond-Blackfan anemia. Disc Medicine targets the hepcidin metabolism axis and aims to modify fundamental biological pathways related to red blood cell formation and function, including heme biosynthesis and iron homeostasis. Through its portfolio of clinical and preclinical product candidates, the company strives to transform the lives of patients suffering from severe hematologic disorders.

PeopleFund, founded in 2015, is a leading data-driven digital lender in Korea that specializes in consumer finance. The company aims to provide financial freedom by offering affordable loans and attractive investment opportunities. Utilizing a proprietary credit model and advanced technology, PeopleFund enhances loan rates for borrowers while maintaining a low loss rate, benefiting both retail and institutional investors. It has achieved significant milestones, including becoming the first digital lender in Korea to surpass $1 billion in loan originations and serving nearly 400,000 retail investors. Additionally, PeopleFund is recognized for being the first fintech platform to offer loan and investment products through KakaoTalk, a popular messaging application in Korea. The company has successfully completed a Series C funding round, raising $63.4 million in equity capital. Its lending platform integrates with banks and financial institutions to streamline the loan process, making personal loans accessible at competitive interest rates.

EcoCeres is an innovative biomass utilization company with strong R&D capability and excellent ESG performance. EcoCeres focuses on the utilization of bio-grease and agricultural waste. EcoCeres creates decarbonization solutions to help the world achieve carbon neutrality.

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cardio-metabolic diseases. The company aims to enhance patient care for individuals with metabolic disorders by addressing the shortcomings of currently available treatments. Its leading product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor designed to effectively lower LDL cholesterol levels while potentially overcoming the limitations associated with existing therapies.

PeopleFund, founded in 2015, is a leading data-driven digital lender in Korea that specializes in consumer finance. The company aims to provide financial freedom by offering affordable loans and attractive investment opportunities. Utilizing a proprietary credit model and advanced technology, PeopleFund enhances loan rates for borrowers while maintaining a low loss rate, benefiting both retail and institutional investors. It has achieved significant milestones, including becoming the first digital lender in Korea to surpass $1 billion in loan originations and serving nearly 400,000 retail investors. Additionally, PeopleFund is recognized for being the first fintech platform to offer loan and investment products through KakaoTalk, a popular messaging application in Korea. The company has successfully completed a Series C funding round, raising $63.4 million in equity capital. Its lending platform integrates with banks and financial institutions to streamline the loan process, making personal loans accessible at competitive interest rates.

About the business that each mash group company develops.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients’ muscles. DMD is a progressive and ultimately fatal condition, with an estimated prevalence of 10,000 to 15,000 cases in the United States. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which targets the LTBP4 protein to reduce fibrosis and inflammation. The company also develops biomarkers, sensors, and the Solid Suit program, which includes wearable assistive devices designed to provide functional and therapeutic benefits. Established in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences collaborates with Ultragenyx to enhance its gene therapy initiatives for DMD.

Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health. Rivus Pharmaceuticals is dedicated to improving cardio-metabolic health by developing controlled metabolic accelerators (CMAs) that address the underlying metabolic risk factors for cardiovascular mortality and morbidity.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

JenaValve Technology, Inc. is a medical device company specializing in the development and manufacturing of transcatheter aortic valve replacement (TAVR) systems designed for patients with severe aortic stenosis and aortic regurgitation. The company's flagship product, the Trilogy Heart Valve System, features a porcine pericardial trileaflet valve mounted on a self-expanding nitinol frame, which allows for both transapical and transfemoral implantation. This innovative system is particularly aimed at high-risk patients and has received CE Mark approval, as well as Breakthrough Device Designation from the U.S. Food and Drug Administration to expedite its review process in the United States. JenaValve operates from its headquarters in Irvine, California, with additional facilities in Munich, Germany, and Leeds, United Kingdom. The company aims to transform the treatment landscape for heart valve diseases through its advanced technologies.

Olympus provides an industry-leading portfolio of innovative test, measurement, and imaging instruments. Leading edge testing technologies include remote visual inspection, microscopy, ultrasound, phased array, eddy current, eddy current array, X-ray fluorescence and diffraction, and optical metrology.

Merchants Fleet is the fastest growing fleet management company nationally. Merchants provides clients with the most high-touch service and innovative experience across the industry for fleets, with flexible terms from three months to seven years. Our unique technology platforms coupled with specialized fleet teams provide the most comprehensive FleetTech solutions to drive proven results.

Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication of improving lung function and is found in several asthma-related treatments.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from classical complement-mediated disorders affecting the body, brain, and eye. The company's research is centered around its platform technology that targets classical complement-mediated autoimmune and neurodegenerative diseases associated with the abnormal activation of C1q, a key molecule in the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody intended for intravenous use in treating autoimmune and neurodegenerative disorders. Another candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration aimed at neurodegenerative ophthalmic conditions. The company employs a disciplined, biomarker-driven development strategy to ensure its therapies effectively engage the target at tolerable doses within the intended patient tissues, while also exploring additional indications within both orphan and larger market segments.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for primary immune deficiencies and cancer. The company's lead candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. It is in Phase III for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and in Phase Ib for severe congenital neutropenia and Waldenström macroglobulinemia. Additionally, mavorixafor is being explored in Phase IIa trials for clear cell renal cell carcinoma. X4 Pharmaceuticals is also advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 for primary immune deficiencies. The company has partnered with Abbisko Therapeutics Co., Ltd. to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. and rebranded in March 2019.

Bubbles is a collaboration tool that lets's tag anything on screen and invite teammates to discuss in-context. Get excited by organic growth and viral loops, and less so by paid advertising. Are active on one or more social platforms like Medium, Twitter, Product Hunt, etc. It was founded in 2018 and is based inSan Francisco, California.

TARC develops housing, commercial premises, hotels, resorts, hospitals, and infrastructure projects.

nGrow.ai is a low-code platform specializing in push notification marketing, designed to enhance revenue generation for mobile applications and games. Launched in November 2021, the company utilizes an AI-driven tool that enables clients to achieve up to 30% incremental revenue growth through effective management of application push notifications. nGrow.ai offers scalable services comprised of various micro-services, which facilitate the efficient handling of marketing campaigns in the push notifications channel, similar to automated marketing solutions provided by major platforms like Google and Facebook. With a daily output of 150 million notifications, nGrow.ai leverages the expertise of its founders, who possess over eight years of experience in merging AI technology with marketing across numerous applications. The company is supported by notable investors from Y Combinator, as well as former executives from Dropbox and Google.

FreeWill is an online platform that specializes in estate planning and charitable giving. Based in New York, the company provides users with free access to legal forms and information, simplifying the process of creating estate plans. It offers various tools designed to facilitate charitable donations, allowing users to make bequests and contributions in a straightforward and tax-advantaged manner. By catering to both donors and fundraisers, FreeWill aims to streamline the donation process, making it easier for individuals to support their chosen causes while addressing their estate planning needs.

Overview’s inspection systems are built with Deep Learning technology which allows us to find mistakes more consistently and in a wider variety of situations.

Swoogo is a developer of an event management software platform tailored for business-to-business event marketers. The platform facilitates a range of events, from single-speaker webinars to large-scale global trade shows. It offers features such as optimized event registration and ticketing, customizable themes, and branding options. Swoogo enables marketers to efficiently gather detailed and segmented audience information, accommodating various attendee types through the use of conditional logic. This comprehensive set of tools positions Swoogo as a key player in the dynamic landscape of event management.

Classys is a medical device manufacturer based in Seoul, South Korea, specializing in technology-driven equipment for cosmetic procedures. The company focuses on providing advanced solutions for plastic surgery, anti-aging treatments, and excess fat removal, allowing clients to access high-quality beauty treatments. Through its innovative products, Classys aims to enhance the effectiveness and safety of various cosmetic applications.